Search Results - "Do, Khanh Tu"

Impact of early release of oral investigational prescriptions on safety and efficiency at a comprehensive cancer center by Breaud, Alan H., Szabatura, Audrea H, Cedro, Laura, Shanedling, Anna, Lakhani, Hakim, Caparrotta, Caryn, Mazeika, Teresa, Rompelman, Garrett, Gallant, Amy, Do, Khanh Tu, Bartel, Sylvia

“…Abstract only 257 Background: At Dana-Farber Cancer Institute (DFCI), timing of order release to the pharmacy is a contributing factor to safety and processing…”
Get full text

Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts by Matrana, Marc Ryan, Tsai, Frank, Cleary, James M., Satti, Suma, Borazanci, Erkut, Estes, Jacob, Moser, Justin, Do, Khanh Tu, Du, Lingling, Sharma, Sunil, Khemka, Vivek, Kolmakov, Valentin, Kawabe, Takumi, Shapiro, Geoffrey

“…Abstract only 3059 Background: CBP501 is a 12-amino acid G2 checkpoint abrogator and calmodulin-modulating peptide that increases platinum influx into tumor…”
Get full text

Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors by Lakhani, Nehal J., Gutierrez, Martin, Duska, Linda R., Do, Khanh Tu, Sharma, Manish, Gandhi, Leena, Papadopoulos, Kyriakos P., Truong, Jennifer, Fan, Xiaolin, Lee, Ji Hyun, Bobba, Suresh, Rippley, Ronda, Wu, Rentian, Cui, Jike, Sun, Kaiming, Wang, Jing Y., Trojer, Patrick, Rasco, Drew W.

“…Abstract only 3104 Background: Enhancer of Zeste homolog 2 (EZH2) is a histone methyltransferase and the catalytic subunit of Polycomb Repressive Complex 2…”
Get full text

Algorithmic matching of genomic profiles to precision cancer medicine clinical trials at DFCI by Lindsay, James, Del Vecchio Fitz, Catherine, Zwiesler, Zachary, Kumari, Priti, Do, Khanh Tu, Shapiro, Geoffrey, Cerami, Ethan

“…Abstract only 6620 Background: Genomic profiling and access to precision medicine clinical trials are now standard at leading cancer institutes and many…”
Get full text

Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas by Manji, Gulam Abbas, Van Tine, Brian Andrew, Lee, Shing Mirn, Raufi, Alexander, Patwardhan, Parag, Blumberg, Lauren Esther, Sender, Naomi, Wang, Jennifer, Otap, Daniel, Singh-Kandah, Shahnaz V., Do, Khanh Tu, Hirbe, Angela C., Bollag, Gideon, Schwartz, Gary K.

“…Abstract only 11055 Background: No effective therapy exists for unresectable malignant peripheral nerve sheath tumors (MPNSTs). We previously reported that the…”
Get full text

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab by Patel, Manish R., Bauer, Todd Michael, Jimeno, Antonio, Wang, Ding, LoRusso, Patricia, Do, Khanh Tu, Stemmer, Salomon M., Maurice-Dror, Corinne, Geva, Ravit, Zacharek, Sima, Laino, Andressa S, Sun, Jing, Frederick, Joshua, Zhou, Honghong, Randolph, William, Cohen, Pamela Sarah, Meehan, Robert S., Sullivan, Ryan J.

“…Abstract only 3092 Background: mRNA-2752 is a novel mRNA-based therapeutic agent encoding OX40L T cell co-stimulator, IL-23 and IL-36γ pro-inflammatory…”
Get full text

Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors by Mittra, Arjun, O'Sullivan Coyne, Geraldine Helen, Do, Khanh Tu, Piha-Paul, Sarina Anne, Kummar, Shivaani, Takebe, Naoko, Bruns, Ashley, Juwara, Lamin, Rubinstein, Lawrence, Hogu, Murielle, Kinders, Robert J., Parchment, Ralph E., Miller, Brandon, Wilsker, Deborah, Monge B., M. Cecilia, Khan, Sabrina Sharmin, Doyle, L. Austin, Doroshow, James H., Chen, Alice P.

“…Abstract only 3067 Background: M6620 (M), a potent ATR inhibitor, has synergistic activity with cisplatin (C) in multiple preclinical models, resulting in DNA…”
Get full text

Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors by Do, Khanh Tu, Hays, John L., Liu, Stephen V., Chen, Alice P., O'Sullivan, Geraldine, Supko, Jeffrey G., Beebe, Kristin, Neckers, Len, Trepel, Jane B., Lee, Min-Jung, Gannon, Courtney, Muzikansky, Alona, Campos, Susana M., Downey, Elizabeth, Wolanski, Andrew, Hedglin, Jennifer, Arnaldez, Fernanda Irene, Doroshow, James H., Shapiro, Geoffrey

“…Abstract only 2619 Background: The 90kDa heat shock protein (HSP90) participates in the folding, stabilization, activation, and proteolytic turnover of…”
Get full text

Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors by Manji, Gulam Abbas, Patwardhan, Parag, Lee, Shing Mirn, Matos, Nanette, Bentlyewski, Edward, Van Tine, Brian Andrew, Do, Khanh Tu, George, Suzanne, Schwartz, Gary K.

“…Abstract only…”
Get full text

Abstract B079: Single agent AZD 1775, a Wee1 inhibitor, shows activity in BRCA deficient patients by OSullivan Coyne, Geraldine, Kummar, Shivaani, Takebe, Naoko, Do, Khanh Tu, Meehan, Robert, Piekarz, Richard, Zlott, Jennifer, Juwara, Lamin, Quinn, Mary, Sharon, Elad, Streicher, Howard, Rubinstein, Lawrence, Levine, Chana, Doroshow, James H., Chen, Alice P.

“…Abstract Background: Modulation of BRCA1 and ATR has been postulated as an activation mechanism of checkpoint 1 (Chk1), which in turn triggers homologous…”
Get full text

Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients by Pollack, Seth, Lu, Hailing, Somaiah, Neeta, Chawla, Sant P., Morris, John Charles, Do, Khanh Tu, Kim, Joseph W., Block, Matthew Stephen, Vignali, Marissa, Rytlewski, Julie, Yusko, Erik, Hsu, Frank J., Bohac, Gerry C., Gnjatic, Sacha, Ter Meulen, Jan

“…Abstract only 3090 Background: The correlation of immune response (IR) and clinical benefit in patients (pts) who receive active immunotherapy remains…”
Get full text

Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS) by Somaiah, Neeta, Chawla, Sant P., Block, Matthew Stephen, Morris, John Charles, Do, Khanh Tu, Kim, Joseph W., Druta, Mihaela, Sankhala, Kamalesh Kumar, Hwu, Patrick, Gnjatic, Sacha, Lu, Hailing, Kenney, Richard T., Bohac, Gerry C., Pollack, Seth

“…Abstract only 11006 Background: CMB305 is an active immunotherapy regimen designed to generate and expand anti-NY-ESO-1 T cells. It consists of LV305, a…”
Get full text

Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors by O'Sullivan Coyne, Geraldine Helen, Do, Khanh Tu, Kummar, Shivaani, Takebe, Naoko, Quinn, Mary Flanagan, Piha-Paul, Sarina Anne, Bruns, Ashley, Juwara, Lamin, Sharon, Elad, Piekarz, Richard, Streicher, Howard, Rubinstein, Larry, Wilsker, Deborah, Kinders, Robert J., Parchment, Ralph E., Levy, Elliot B, Doyle, Austin, Doroshow, James H., Chen, Alice P.

“…Abstract only…”
Get full text

Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775 by Takebe, Naoko, O'Sullivan Coyne, Geraldine Helen, Kummar, Shivaani, Do, Khanh Tu, Bruns, Ashley, Juwara, Lamin, Quinn, Mary Flanagan, Harris, Lyndsay, Piekarz, Richard, Prindiville, Sheila Ann, Sharon, Elad, Streicher, Howard, Mugundu, Ganesh, Ji, Jiuping Jay, Wilsker, Deborah, Kinders, Robert J., Rubinstein, Larry, Doroshow, James H., Chen, Alice P.

“…Abstract only…”
Get full text

Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1 by Somaiah, Neeta, Block, Matthew Stephen, Kim, Joseph W., Shapiro, Geoffrey, Do, Khanh Tu, Hwu, Patrick, Eder, Joseph Paul, Jones, Robin Lewis, Gnjatic, Sacha, Lu, Hailing, Ter Meulen, Jan, Hsu, Frank J., Pollack, Seth

“…Abstract only…”
Get full text

A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors by Nayak, Lakshmi, Hays, John L., Muzikansky, Alona, Gaffey, Sarah C., Do, Khanh Tu, Puduvalli, Vinay K., Lee, Eudocia Quant, Rinne, Mikael L., Norden, Andrew David, Beroukhim, Rameen, Wen, Patrick Y., Doyle, L. Austin, Chen, Helen X., Shapiro, Geoffrey, Reardon, David A.

“…Abstract only…”
Get full text

Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis by O'Sullivan Coyne, Geraldine Helen, Kummar, Shivaani, Do, Khanh Tu, Choyke, Peter L., Turkbey, Baris, Polley, Eric, Horneffer, Yvonne, Juwara, Lamin, Vilimas, Rasa J, Meehan, Robert S., Helman, Lee J., Doroshow, James H., Chen, Alice P.

“…Abstract only…”
Get full text

Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors by Do, Khanh Tu, Chen, Alice P., Meehan, Robert S., O'Sullivan Coyne, Geraldine Helen, Supko, Jeffrey G., Trepel, Jane B, Clark, Jeffrey W., Hays, John L., Lyons, John F., Keer, Harold N., Hewes, Julia, Sze, Cameron, Marzano, Marissa, Bhushan, Ketki, Muzikansky, Alona, Ivy, S. Percy, Doroshow, James H., Shapiro, Geoffrey

“…Abstract only TPS2617 Background: The 90kDa heat shock chaperone protein (HSP90) exerts housekeeping functions within cells. HSP90 participates in the folding,…”
Get full text

Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors by Do, Khanh Tu, Wilsker, Deborah, Balasubramanian, Priya, Zlott, Jennifer, Jeong, Woondong, Lawrence, Scott M, Kinders, Robert J., Collins, Jerry, Chen, Alice P., Doroshow, James H., Kummar, Shivaani

“…Abstract only…”
Get full text

Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis by Kummar, Shivaani, Do, Khanh Tu, O'Sullivan Coyne, Geraldine Helen, Turkbey, Baris, Meltzer, Paul S., Polley, Eric, Horneffer, Yvonne, Juwara, Lamin, Antony, Ramya, Choyke, Peter L., Mitchell, Sandra A., Helman, Lee J., Chen, Alice, Doroshow, James H.

“…Abstract only…”
Get full text